98%
921
2 minutes
20
Objectives: Reliable prognostic tools are essential for improving the management of stage I non-small cell lung cancer. Whereas fluorodeoxyglucose positron emission tomography has proven valuable, metrics such as maximum standardized uptake value are limited by interinstitutional variability. This study evaluates the Deauville score for its clinical utility in predicting pathological invasiveness and survival outcomes.
Methods: Data were retrospectively collected from 495 patients with stage I non-small cell lung cancer who underwent pulmonary resection across 4 institutions in Japan. Tumors were classified by a visual 5-point scale Deauville scores into groups: 1 and 2, 3, and 4 and 5. Associations between these scores, pathological invasiveness (defined as lymphatic invasion, vascular invasion, pleural invasion, and/or nodal involvement), and survival outcomes were analyzed.
Results: High Deauville scores (4 and 5) were significantly associated with pure solid tumors (85%; P < .0001) and pathological invasiveness (66%; P < .0001). Multivariable analysis showed the Deauville score to be an independent predictor of invasiveness (odds ratio, 10.145; P < .0001 for scores 4 and 5 vs 1 and 2). Survival analyses revealed poorer outcomes for patients with scores of 4 and 5, with a 5-year recurrence-free survival of approximately 60% (P < .0001). Even in part-solid tumors, scores of 4 and 5 were linked to significantly worse recurrence-free survival compared with scores of 1 and 2 or 3 (P < .0001).
Conclusions: The Deauville score provides a straightforward and consistent method to predict pathological invasiveness and survival in stage I non-small cell lung cancer. Its reliability and reproducibility across institutions highlight its potential as a valuable tool for both clinical practice and large-scale research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jtcvs.2025.07.011 | DOI Listing |
Br J Haematol
August 2025
Department of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Relapse remains the primary cause of transplant failure in T-cell lymphoblastic lymphoma (T-LBL) after allogeneic haematopoietic stem cell transplantation (allo-HSCT), yet prognostic data are scarce. We conducted a multicentre retrospective study of 104 adult T-LBL patients in complete metabolic remission (CMR) undergoing allo-HSCT. Pretransplant Deauville score (DS) was evaluated, and a risk model integrating DS, immunophenotype and donor type was developed.
View Article and Find Full Text PDFBlood Adv
August 2025
Memorial Sloan Kettering Cancer Center, New York, New York, United States.
In the phase 3 ECHELON-2 trial, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) significantly improved progression-free survival (PFS) and overall survival (OS) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30+ peripheral T-cell lymphoma (PTCL), benefits that were maintained at 5 years. Interim positron emission tomography (PET) scan can be used to assess prognosis and risk stratify patients. The prognostic value of interim PET was assessed in this post hoc exploratory analysis from ECHELON-2 evaluating interim 18F-FDG PET scans after cycle 4 (PET4) and end-of-treatment-based response and correlated with PFS per investigator and OS.
View Article and Find Full Text PDFJ Nucl Med
September 2025
Department of Radiology, University of California Davis, Sacramento, California.
The improved sensitivity of total-body (TB) PET/CT offers the possibility of reducing injected activities. The aim of our study was to define a lower limit of reduced injected activities in [F]FDG TB PET/CT for interim and end-of-treatment assessment of patients with lymphoma at 2 acquisition times. Twenty-four consecutive patients with lymphoma who were undergoing interim and end-of-treatment TB PET/CT were prospectively enrolled in this study.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
July 2025
Cancer services, Austin Health, Melbourne, Victoria, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia; Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia. Electronic address:
Background: In classical Hodgkin lymphoma (cHL), interim positron emission tomography (iPET) using Deauville Score (DS) guides therapy. Quantitative PET parameters, including changes in maximum standard uptake value [ΔSUVmax], total metabolic tumor volume [ΔTMTV], total lesion glycolysis [ΔTLG], may enhance the predictive value of iPET.
Methods: This retrospective study analysed 98 cHL patients from 2008 to 2022, assessing quantitative PET parameters at baseline (PET0), after 2 or 3 chemotherapy cycles (iPET), and associations with survival outcomes.
Hell J Nucl Med
August 2025
Center for Nuclear Medicine with PET, University Clinical Center of Serbia, Belgrade, Serbia.
Objective: The aim of this study is to determine the importance of different fluorine-18-fluorodeoxyglucose (F-FDG) positron emission tomography with computed tomography (PET/CT) semi-quantitative and quantitative parameters, as well as various clinical and demographic parameters, in predicting disease outcomes and response to therapy in patients with diffuse large B-cell lymphoma (DLBCL).
Subjects And Methods: The study included 64 patients diagnosed with DLBCL who underwent F-FDG PET/CT imaging between January 2020 and April 2023. Each patient underwent both an initial F-FDG PET/CT and an interim F-FDG PET/CT after 2 or 4 cycles of chemotherapy.